Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Peginterferon Lambda  COVID-19 treatment studies for Peg.. Lambda  C19 studies: Peg.. Lambda  Peg.. Lambda   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ ICU admission -200% Improvement Relative Risk Hospitalization time -25% Viral clearance, day 14 12% Viral clearance, day 7 -67% Kim et al. NCT04343976 Peg.. Lambda for COVID-19 RCT LATE Is late treatment with peginterferon lambda beneficial for COVID-19? RCT 14 patients in the USA (July 2020 - July 2021) Longer hospitalization with peginterferon lambda (not stat. sig., p=0.59) Kim et al., Frontiers in Medicine, doi:10.3389/fmed.2023.1095828 Favors peg.. lambda Favors control
Peginterferon lambda for the treatment of hospitalized patients with mild COVID-19: A pilot phase 2 randomized placebo-controlled trial
Kim et al., Frontiers in Medicine, doi:10.3389/fmed.2023.1095828, NCT04343976 (history)
Kim et al., Peginterferon lambda for the treatment of hospitalized patients with mild COVID-19: A pilot phase 2 randomized.., Frontiers in Medicine, doi:10.3389/fmed.2023.1095828, NCT04343976
Feb 2023   Source   PDF  
  All Studies   Meta
Very small RCT with 14 hospitalized patients in the USA showing no significant differences with peginterferon lambda. Viral load was improved, however 86% of treatment versus 14% of control patients received remdesivir, and the median baseline viral load for treatment patients was 3.6 log10 copies/ml versus 0 for control.
risk of ICU admission, 200.0% higher, RR 3.00, p = 1.00, treatment 1 of 7 (14.3%), control 0 of 7 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm).
hospitalization time, 25.0% higher, relative time 1.25, p = 0.59, treatment median 5.0 IQR 4.0 n=7, control median 4.0 IQR 5.0 n=7.
risk of no viral clearance, 12.5% lower, RR 0.88, p = 1.00, treatment 3 of 6 (50.0%), control 4 of 7 (57.1%), NNT 14, day 14.
risk of no viral clearance, 66.7% higher, RR 1.67, p = 0.59, treatment 5 of 7 (71.4%), control 3 of 7 (42.9%), day 7.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Kim et al., 24 Feb 2023, Single Blind Randomized Controlled Trial, placebo-controlled, USA, peer-reviewed, median age 54.0, 9 authors, study period 14 July, 2020 - 16 July, 2021, trial NCT04343976 (history).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperPeg.. LambdaAll
Abstract: TYPE Clinical Trial PUBLISHED 24 February 2023 DOI 10.3389/fmed.2023.1095828 OPEN ACCESS EDITED BY Shisan (Bob) Bao, The University of Sydney, Australia REVIEWED BY Connor Bamford, Queen's University Belfast, United Kingdom Bryan D. Kraft, Duke University, United States *CORRESPONDENCE Raymond T. Chung Peginterferon lambda for the treatment of hospitalized patients with mild COVID-19: A pilot phase 2 randomized placebo-controlled trial Myung-Ho Kim 1,2, Josh Elbaz 1,3, Nikolaus Jilg 4,5, Jenna L. Gustafson 1,5, Min Xu 1,5, Dilara Hatipoglu 5, Eric Nohelty 4,5, Arthur Y. Kim 4,5 and Raymond T. Chung 1,5* Liver Center, Gastrointestinal Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States, 2 Department of Internal Korean Medicine, Woosuk University Medical Center, Jeonju, Republic of Korea, 3 Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, United States, 4 Division of Infectious Disease, Massachusetts General Hospital, Harvard Medical School Boston, Boston, MA, United States, 5 Department of Medicine, Massachusetts General Hospital, Boston, MA, United States 1 SPECIALTY SECTION This article was submitted to Infectious Diseases: Pathogenesis and Therapy, a section of the journal Frontiers in Medicine RECEIVED 11 November 2022 ACCEPTED 08 February 2023 PUBLISHED 24 February 2023 CITATION Kim MH, Elbaz J, Jilg N, Gustafson JL, Xu M, Hatipoglu D, Nohelty E, Kim AY and Chung RT (2023) Peginterferon lambda for the treatment of hospitalized patients with mild COVID-19: A pilot phase 2 randomized placebo-controlled trial. Front. Med. 10:1095828. doi: 10.3389/fmed.2023.1095828 COPYRIGHT © 2023 Kim, Elbaz, Jilg, Gustafson, Xu, Hatipoglu, Nohelty, Kim and Chung. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. Background: This study aimed to investigate the efficacy and safety of subcutaneous injection of peginterferon lambda in patients hospitalized with COVID-19. Methods: In this study (NCT04343976), patients admitted to hospital with COVID-19 confirmed by RT-PCR from nasopharyngeal swab were randomly assigned within 48 h to receive peginterferon lambda or placebo in a 1:1 ratio. Participants were subcutaneously injected with a peginterferon lambda or saline placebo at baseline and day 7 and were followed up until day 14. Results: We enrolled 14 participants; 6 participants (85.7%) in the peginterferon lambda group and 1 participant (14.3%) in the placebo group were treated with remdesivir prior to enrollment. Fifty percent of participants were SARS-CoV-2 RNA negative at baseline although they tested SARS-CoV-2 RNA positive within 48h of randomization. Among participants who were SARS-CoV-2 positive at baseline, 2 out of 5 participants (40%) in the peginterferon lambda group became negative at day 14, while 0 out of 2 participants (0%) in the placebo group achieved negativity for SARS-CoV-2 by day 14 (p>0.05). The median change in viral load (log copies per ml) was +1.72 (IQR −2.78 to 3.19) in the placebo group and −2.22..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop